Anderlecht

Belgium

445 total trials 182 recruiting

Filter these 445 trials by phase, condition, sponsor and more.

Open in Search →

Acute-On-Chronic Liver Failure (ACLF) at High Risk of Hospital Mortality Ended

2022-502187-20-00 5 2019-04-11 Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected eith
Study of IPH4102 alone or in combination with chemotherapy in patients with Advanced T-cell Lymphoma. Ended

2023-507777-18-00 4 2019-03-19 Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabin … Ended

2024-513513-12-00 5 2019-01-06 Cholangiocarcinoma
RCT part: COBRA-Slim with or without fast access to TNF blockade for remission induction in early RA. LTE part: Long Term observational fol … Ended

2023-510189-28-00 6 2018-05-15 Rheumatoid Arthritis
PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended

2022-500251-22-00 4 2018-04-12 This study will include all patients having received at least one infu
Perioperative treatment of locally advanced resectable gastric or GEJ adenocarcinoma Ended

2023-509595-42-00 5 2017-10-31 Gastric and gastroesophageal junction (GEJ) adenocarcinoma
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha … Ended

2024-511967-26-00 5 2016-11-21 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended

2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer Ended

2024-516004-42-01 4 2014-05-14 MSI Negative Colorectal Cancer
Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended

2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan … Ended

2023-506487-13-00 5 Hormone receptor-positive, her2-negative advanced/metastatic breast ca
Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended

2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
A Study of EOS006215 in Adult Participants with Advanced Solid Tumors Ended

2024-520369-30-00 1 Solid Tumors

Showing 433–445 of 445 trials